Pharmacological Results
We studied the pharmacokinetics of ropivacaine after a continuous SAPB
injection in 88 patients aged 18-70 years with BMI 18-30
kg/m2 (44 patients in each group). All expected blood
samples were collected. The peak total plasma concentrations of
ropivacaine were 2.93
μg·mL−1 in Group H
and 2.01 μg·mL−1 in Group L 48 hours after injection
(Figure 2). The maximum total plasma level of ropivacaine was still well
below the theoretical toxicity threshold of 3.40
μg·mL−1[18].